Sanofi has nominated Bonnie Bassler to its board of directors as an independent member.
Ms Bassler currently serves as a member of the US National Science Board, which oversees the National Science Foundation. She was appointed to the role shortly after CEO Christoper Viehbacher was sacked by the board.
Bassler has over two decades of experience in the scientific sector and is a Howard Hughes Medical Institute investigator, professor in molecular biology and chair of the department of molecular biology at Princeton University.
She also serves on oversight, grant, fellowship and award panels for organisations including the National Academies of Sciences and US National Institutes of Health.
Ms Bassler said: “It is a great honour for me to join Sanofi’s board of directors. Sanofi is one of the leading international pharmaceutical companies in the world and I look forward to working closely with members on the board and the company to support Sanofi’s mission to develop and introduce innovative therapies.”
Serge Weinberg, chairman of the board and interim CEO at Sanofi, said: “Professor Bassler’s scientific expertise in molecular biology and her great leadership skills makes her an outstanding addition to our board. We look forward to her contribution to Sanofi’s strategy as we continue to innovate and introduce new medicines and vaccines that can help improve health outcomes.”